Skip to main content
MEDICINOVA INC logo

MEDICINOVA INC — Investor Relations & Filings

Ticker · MNOV Manufacturing
Filings indexed 37 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country US United States of America
Listing MNOV

About MEDICINOVA INC

https://medicinova.com/

MediciNova Inc. is a biopharmaceutical company focused on developing novel small molecule therapeutics for serious diseases with unmet medical needs. Its pipeline targets neurology, respiratory, and liver diseases. Key product candidates include MN-166 (ibudilast), which is being developed for indications such as Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis, Oncology/Glioblastoma, Chemotherapy-Induced Peripheral Neuropathy (CIPN), and Acute Respiratory Distress Syndrome (ARDS)/Lung Injury. MN-166 has also been marketed in Japan and Korea for post-stroke complications and bronchial asthma. Another candidate, MN-001 (tipelukast), is in development for Non-Alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes Mellitus, and Hypertriglyceridemia. The company's mission involves acquiring and accelerating the global development and commercialization of these therapeutics.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report
2026-05-14 English
ARS
Annual Report
2026-04-29 English
DEFA14A
Proxy Solicitation & Information Statement
2026-04-29 English
DEF 14A
Proxy Solicitation & Information Statement
2026-04-29 English
PRER14A
Regulatory Filings
2026-04-20 English
PRE 14A
Regulatory Filings
2026-04-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.